抗纤颗粒治疗慢性肝病肝纤维化的临床研究

    谢朝良 何庆玲* 杨华秀 刘鹏 汪静 米绍平

    【摘要】 目的：为探讨抗纤维颗粒治疗肝纤维化患者的疗效。方法：将45例肝纤维化患者按2:1随机分为试验组30例和对照组15例，治疗前后观察45例患者临床症状、肝脏B超变化、肝功能及血清HA、PCⅢ、LN水平的变化。结果：(1)总有效率：试验组96.7%显著高于对照组66.7%(P<0.01)；(2)两组治疗后血清ALT、AST含量均显蓍降低，但两组之间比较无统计学差异(P>0.05)；(3)试验组在降低血清球蛋白及r-球蛋白比例方面，极显著优于对照组(P<0.01)；(4)试验组与对照组均能极显著降低血清HA、LN、PCⅢ含量(P<0.01)，但试验组作用极显著优于对照组(P<0.01)。结论：抗纤颗粒治疗肝纤维化患者具有消除或减轻临床症状、软缩肝脾、恢复肝功能及抗肝纤维化等作用。

    【关键词】 抗纤颗粒；肝纤维化；透明质酸；层粘连蛋白；Ⅲ型前胶原；临床研究

    Clinical study of chronic hepatic fibrosis treated by Kangxiankeli

    Xie Chaoliang, He Qinling, Yang Huaxie, Lliu Peng, Wang Jing, Mi Shaoping；Affiliated Hopital of TCM, Luzhou Medical College, 646000

    【Abstract】Objective: To investigate the effects of Kangxiankeli in treating the patients with hepaticfibrosis. Methods: 45 patients of chronic hepatitis were divided randomly into observed (30 cases) and control (15 cases) group, the observed group treated with Kangxiankeli, the control group with BieJiaJianWan. Before and after the treatment, the clinical symptoms and signs, liver function, and Bmode ultrasonic change of liver, PC-III, LN, HA in erum were compared. Results: The total curative rates in the observed group was significantly higher than that in the control group (P<0.01). The ALT and AST remarkably decreased after treatment, but without statistical significance in the both groups (P>0.05). The gamma-globin and globin decreased more in the observed group than in the control group with significant statistical difference (P<0.01). The HA, LN and PCIII in the serum in the observed group reduced significantly more than those in the control group (P>0.01). Conclusion: The curative effects of Kangxiankeli in treating hepatic fibrosis were relieving and eradicating the clinic symptoms, softening the liver and spleen, improving the function of liver, reducing thee fibrosis. ......